ING Groep NV Buys New Shares in Amgen Inc. $AMGN

Key Points

• ING Groep NV disclosed a new fourth-quarter stake in Amgen, buying 2,988 shares worth about $978,000. Other institutions also added to positions, and institutional ownership now stands at 76.5%.
• Amgen reported strong quarterly results, with EPS of $5.15 beating estimates and revenue of $8.62 billion edging above forecasts. The company also raised its FY2026 guidance to 21.7–23.1 EPS.
• Analysts remain mixed on the stock: some raised or maintained positive ratings, but the overall consensus is still “Hold” with an average price target of $354.12. Recent commentary highlights both optimism around the obesity drug MariTide and concerns about short-term underperformance and patent pressure.

ING Groep NV bought a new stake in Amgen Inc. (NASDAQ:AMGN - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 2,988 shares of the medical research company's stock, valued at approximately $978,000.

Other institutional investors have also added to or reduced their stakes in the company. Dogwood Wealth Management LLC increased its holdings in shares of Amgen by 275.0% in the fourth quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company's stock worth $25,000 after buying an additional 55 shares during the period. Anfield Capital Management LLC lifted its stake in shares of Amgen by 1,000.0% in the 4th quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company's stock valued at $25,000 after acquiring an additional 70 shares during the last quarter. Board of the Pension Protection Fund purchased a new stake in Amgen during the 4th quarter valued at about $26,000. Manning & Napier Advisors LLC grew its position in Amgen by 49.2% during the 4th quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company's stock worth $32,000 after acquiring an additional 32 shares during the last quarter. Finally, Olistico Wealth LLC bought a new position in Amgen during the 4th quarter worth approximately $33,000. Institutional investors own 76.50% of the company's stock.

Insider Buying and Selling

In other news, SVP Nancy A. Grygiel sold 1,237 shares of the firm's stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $323.73, for a total value of $400,454.01. Following the completion of the sale, the senior vice president directly owned 7,009 shares of the company's stock, valued at approximately $2,269,023.57. This trade represents a 15.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 0.85% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts have weighed in on AMGN shares. Piper Sandler lowered their price objective on Amgen from $432.00 to $427.00 and set an "overweight" rating for the company in a research report on Thursday, May 14th. Canaccord Genuity Group started coverage on shares of Amgen in a report on Monday, April 20th. They issued a "hold" rating and a $366.00 target price on the stock. Morgan Stanley upped their price target on shares of Amgen from $332.00 to $340.00 and gave the company an "equal weight" rating in a report on Tuesday. Wells Fargo & Company increased their price target on shares of Amgen from $375.00 to $390.00 and gave the company an "equal weight" rating in a research report on Thursday, March 19th. Finally, Royal Bank Of Canada raised their price target on shares of Amgen from $360.00 to $370.00 and gave the stock an "outperform" rating in a report on Tuesday, April 7th. Two analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, fourteen have given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, Amgen currently has an average rating of "Hold" and an average price target of $354.12.

Key Stories Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen’s obesity drug MariTide is drawing attention as a potential growth driver, with analysts noting that its less frequent dosing could help the company compete in the fast-growing GLP-1/obesity market. Article Title
• Positive Sentiment: Amgen’s broader growth pipeline is being viewed as a potential offset to patent-related pressure, with some commentary suggesting 2026 could be a “springboard” year if newer drugs gain traction. Article Title
• Neutral Sentiment: Goldman Sachs trimmed its price target on Amgen but kept a Buy rating, signaling some caution on valuation while still seeing upside potential. Article Title
• Neutral Sentiment: Recent market commentary noted that Amgen has underperformed some peers and posted a bigger drop than the broader market, reflecting short-term profit-taking and weaker relative momentum. Article Title
• Negative Sentiment: Market coverage also flagged that Amgen fell more than the market in the latest session, reinforcing concern that investors may be locking in gains after the stock’s strong multi-year run. Article Title

Amgen Price Performance

AMGN opened at $337.73 on Thursday. The company has a debt-to-equity ratio of 5.65, a quick ratio of 1.01 and a current ratio of 1.26. The stock has a market capitalization of $182.28 billion, a PE ratio of 23.50, a price-to-earnings-growth ratio of 3.46 and a beta of 0.42. The stock's 50 day moving average price is $340.89 and its 200-day moving average price is $345.53. Amgen Inc. has a 52-week low of $267.83 and a 52-week high of $391.29.

Amgen (NASDAQ:AMGN - Get Free Report) last announced its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, topping analysts' consensus estimates of $4.77 by $0.38. The company had revenue of $8.62 billion during the quarter, compared to analyst estimates of $8.58 billion. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The firm's revenue was up 5.8% on a year-over-year basis. During the same quarter last year, the firm posted $4.90 earnings per share. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. On average, equities research analysts predict that Amgen Inc. will post 22.38 EPS for the current year.

Amgen Profile

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.